Initiation Reports


Exactus seeking prime position in hemp cannabinoids

Following enactment of ‘the Farm Bill’ in the US in January 2019, legalising hemp...

on 24/10/19

BevCanna - Emerging leader in infused beverage innovations

BevCanna Enterprises Inc (CNSX:BEV) offers investors an early-stage opportunity in the emerging...

on 7/10/19

Enteq Upstream - Knowing the drill

Enteq upstream (LON:NTQ) is a leading supplier of high-end systems and products for measurement...

on 27/9/19

Georgina Energy - upcoming IPO

Georgina Energy is an energy company offering investors exposure to an increasingly...

on 9/9/19



Open Orphan: Leveraging expertise and relationships for growth

Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic European orphan...

1 week, 3 days ago

Enteq Upstream - Expansion strategy drives strong interim results

Enteq Upstream PLC (LON:NTQ) is a leading technology provider to the global oil & gas...

3 weeks ago

Shield Therapeutics PLC: Hitting its clinical targets

Shield Therapeutics (LON:STX) has reported further data from its non-inferiority AEGIS H2H study...

on 29/10/19

Gfinity - Building on leadership in esport

Gfinity (LON:GFIN) is a world leader in the fast-growing market for esports. The company...

on 29/10/19

Analyst interviews

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular...

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use. They've announced seven clinical/commercial partnership deals...

8 hours, 54 minutes ago